← Treatments
CHICOVERY

ADHD: non-stimulant and integrative treatment

For parents who deliberately want to explore a non-stimulant route first, China may be of interest because of the combination of child psychiatric assessment, behavioural therapy and standardised Chinese medicinal products such as Jingling Oral Liquid.

Evidence status: Promising, but not a proven replacement for standard medication

What is the medical problem?

Stimulants such as methylphenidate are effective for many children, but some parents prefer not to use them or children experience insufficient benefit, appetite loss, weight loss, sleep problems or other side effects.

Which options are being considered?

  • reconfirm the ADHD diagnosis
  • determine subtype and comorbidity
  • parent training and behavioural therapy
  • school and sleep interventions
  • Jingling Oral Liquid as a standardised Chinese non-stimulant medicinal treatment under specialist supervision
  • objective symptom measurements
  • a medication-sparing pathway in which existing medication is adjusted only after demonstrable improvement and under specialist supervision

What could a treatment pathway look like?

Baseline assessment includes ADHD-RS, SNAP-IV or Conners, parent and school reports, height, weight, sleep and relevant comorbidity. This is followed by 8–12 weeks of controlled treatment and repeat measurement using the same instruments. A pathway should demonstrate functional improvement before it is continued.

What do we know about effectiveness?

A modern multicentre, randomised, double-blind placebo-controlled trial found improvement in total ADHD score with Jingling, particularly hyperactivity and impulsivity. Older Chinese comparisons with methylphenidate are promising but methodologically insufficient to claim that Jingling is ‘as good as Ritalin’. It should be regarded as a pharmacologically active treatment, not as a harmless dietary supplement.

Important selection considerations

Medical selection is essential in children. Existing ADHD medication must not be stopped abruptly. Growth, weight, appetite, sleep, behaviour, possible interactions and, during prolonged use when appropriate, liver and kidney function should be monitored.

Medical selection before travel

The options described are not a guarantee of treatment. Availability and suitability depend on diagnosis, indication, evidence level, individual risks and assessment by the treating medical team. Experimental care is identified as such.

Would you like to know whether a pathway could be medically appropriate?

A treatment journey always begins with an assessment of the diagnosis, medical history, previous treatments, medication, risks and the specific treatment objective.

Start medical intake